| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vaxart Inc. | VXA-CoV2-1 | COVID-19 Vaccine (oral), Omicron variant | Phase 2 | Ongoing | Oral | COVID-19 |
| Vaxart Inc. | Norovirus vaccine - (booster) | Norovirus vaccine | Phase 2 | Oral | Immunology | |
| Vaxart Inc. | Norovirus vaccine (VXA-NVV-104) | Norovirus vaccine | Phase 2 | Looking for Funding | Oral | Immunology |
| Vaxart Inc. | BTA074 5% topical gel (teslexivir) | Condyloma | Phase 2 | Topical | N/A | |
| Vaxcyte Inc. | VAX-24 | Pneumococcal conjugate vaccine | Phase 3 | Ongoing | Intramuscular | Immunology |
| Vaxcyte Inc. | VAX-31 - (OPUS) | Invasive Pneumococcal Disease (IPD) | Phase 2 | Data Released | oral | Immunology |
| Vaxcyte Inc. | VAX-24 | Pneumococcal Disease in infants | Phase 2 | Enrollment Conclusion | Intramuscular | Immunology |
| VBI Vaccines Inc. | Sci-B-Vac - (CONSTANT) | Hepatitis B vaccine | Phase 3 | Intramuscular | Immunology |